Burning Rock Biotech (BNR) Q4 2024 earnings summary

Executive summary

• Achieved commercial breakeven in FY2024 (excluding R&D), with ongoing organizational optimization and efficiency gains.

• Expanded NGS-based precision oncology to earlier-stage and asymptomatic populations, with new business lines in early detection and MRD.

• Maintained leadership in multi-cancer early detection and MRD, supported by strong clinical validation, regulatory progress, and inclusion of the THUNDER study in national guidelines.

• Presented significant clinical study results at major conferences and announced a new CDx collaboration with Bayer.

• Received FDA and China NMPA breakthrough device designations and NMPA approval for the first co-developed NGS-based CDx for lung cancer.

Financial highlights

• FY2024 revenues were RMB 516.0 million, down 4% year-over-year; Q4 revenues RMB 126.1 million, up 4.1% year-over-year.

• Non-GAAP gross profit for FY2024 was RMB 386.3 million; Q4 non-GAAP gross profit RMB 93.6 million.

• Q4 gross margin improved to 71.0% from 64.5% prior year; full year gross margin increased to 70.3% from 67.6%.

• Q4 net loss narrowed to RMB81.3 million from RMB162.2 million; full year net loss reduced to RMB346.6 million from RMB653.7 million.

• Cash, cash equivalents, and restricted cash totaled RMB522.2 million at year-end 2024.

Outlook and guidance

• Management continues to focus on profitability-driven measures, including cost controls, margin improvement, and operational efficiency.

• Selling expense ratio expected to remain below 40% of revenue going forward.